Research ArticleInfectious Disease

Chimpanzee adenovirus– and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

See allHide authors and affiliations

Science Translational Medicine  12 Aug 2015:
Vol. 7, Issue 300, pp. 300ra126
DOI: 10.1126/scitranslmed.aac5745

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

RSV vaccine cows infection

Respiratory syncytial virus (RSV) causes a severe lower respiratory tract disease that affects both children and the elderly. Vaccines have shown promise in rodents and nonhuman primates, but it remains unclear if these models reflect human RSV infection. Now, two papers by Taylor et al. and Green et al. translate one vaccine strategy first into calves, which are natural hosts of bovine RSV, and then into humans in a phase 1 clinical trial. A prime-boost strategy protected against upper and lower respiratory tract infection and pulmonary disease induced by heterologous bovine RSV challenge in calves and demonstrated safety and immunogenicity in humans. These data support further trials to test vaccine efficacy in human patients.